New Opportunities, New Challenges: FDA Elaborates on use of

This is Part 1 in a series of blog posts on developments from the U.S. Food and Drug Administration (“FDA”) regarding its commitments set forth under the Prescription Drug Under Fee Act...

Related Keywords

Reed Smith , Steering Committee , Drug Development Tool Qualification Program , Drug Administration , Duke Margolis Center , Product Development , Digital Health Technologies Framework , Clinical Trial Diversity , Drug Omnibus Reform Act , President Biden , Trial Diversity , Prescription Drug User Fee Act , Digital Health Technologies , Biological Product Development , Remote Data Acquisition , Clinical Investigations , Electronic Systems , Electronic Records , Electronic Signatures , Fiscal Year , Health Policy , Understanding Priorities , Support Clinical Trials , Drug Development ,